Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuster ...

Roche will continue a careful approach to high-priced deals, putting science at the center of its business development ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates and improved survival for patients with unresectable hepatocellular ...

The pharmaceutical industry is poised for a dynamic year in 2025. A confluence of positive trends suggests a brighter outlook ...

Partner AstraZeneca’s (AZN) anti-PD-1/TIGIT bispecific antibody rilvegostomig incorporates Compugen technology and is in five Phase 3 trials in lung and biliary tract cancers, Oppenheimer points ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response ...